Eli Lilly transfers sole China rights for its cancer drug to a local partner, and the timing points to a looming problem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results